par Paul Saltet | Déc 12, 2023 | Uncategorized
We are pleased to announce that HEPHAISTOS-Pharma has been awarded a Sanofi’s Golden Ticket 2023, winning a year’s free lab space at BioLabs @Hôtel-Dieu (France) to explore the application of their technology in developing new effective adjuvantation for mRNA...
par Paul Saltet | Nov 12, 2023 | Uncategorized
We are very proud to announce that we are winners of the #EIC_Accelerator grant from the European Innovation Council October 30th 2023. Winners of the EIC accelerator grant have been announced. 47 winning innovative projects have been awarded all over Europe among...
par Paul Saltet | Jan 16, 2023 | Uncategorized
We are very proud to announce that we are winners of the #iNov France2030 Innovation Competitions For this 9th edition, 53 winning innovative projects will be supported by the State via #France2030 for a total amount of €56.3M. The i-Nov innovation competition aims to...
par Paul Saltet | Sep 1, 2022 | Uncategorized
The European Medicines Agency (EMA) has granted Orphan Drug Designation to ONCO-Boost (HEPHAISTOS-Pharma) as treatment for osteosarcoma. Paris, France, September 1st, 2022, 7:00 pm CET. HEPHAISTOS-Pharma a French Biotech company developing a new class of...
par Paul Saltet | Jan 17, 2019 | Uncategorized
HEPHAISTOS-Pharma was present at the Event organized by the University Paris Saclay for its collaborating companies. We are glad to collaborate locally with the University’s research teams, students and teachers and we will continue to collaborate in the...
